Minocycline in amyotrophic lateral sclerosis: A pilot study

Francesco E. Pontieri, A. Ricci, C. Pellicano, D. Benincasa, F. R. Buttarelli

Research output: Contribution to journalArticlepeer-review


Recent studies indicate that minocycline exerts neuroprotective effects in vitro and in vivo, and suggest that the drug may represent a novel therapeutic approach to amyotrophic lateral sclerosis (ALS). In this study we investigated the safety of combined treatment with minocycline and riluzole in ALS. Twenty ALS patients were randomised into two groups and administered either riluzole (50 mg b.i.d.) or riluzole and minocycline (100 mg i.d.) for 6 months. Disease progression was measured by means of the ALS-Functional Rating Scale score at monthly intervals. Respiratory function was measured at the beginning of the study and repeated after 3 and 6 months of treatment. Combined treatment with minocycline and riluzole was not followed by significant side effects. This pilot study shows that minocycline and riluzole can be taken safely together. Further trials are needed to assess efficacy of such treatment.

Original languageEnglish
Pages (from-to)285-287
Number of pages3
JournalNeurological Sciences
Issue number4
Publication statusPublished - Oct 2005


  • Amyotrophic lateral sclerosis
  • Clinical trial
  • Minocycline
  • Riluzole

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Minocycline in amyotrophic lateral sclerosis: A pilot study'. Together they form a unique fingerprint.

Cite this